Söndag 25 Maj | 00:36:59 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-26 07:30 Bokslutskommuniké 2025
2025-11-13 08:30 Kvartalsrapport 2025-Q3
2025-08-21 08:30 Kvartalsrapport 2025-Q2
2025-05-30 N/A X-dag ordinarie utdelning ALZ 0.00 SEK
2025-05-28 N/A Årsstämma
2025-05-15 - Kvartalsrapport 2025-Q1
2025-03-07 - Extra Bolagsstämma 2025
2025-02-27 - Bokslutskommuniké 2024
2024-11-14 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-30 - X-dag ordinarie utdelning ALZ 0.00 SEK
2024-05-29 - Årsstämma
2024-05-28 - Kvartalsrapport 2024-Q1
2024-02-28 - Bokslutskommuniké 2023
2023-11-02 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-30 - Årsstämma
2023-05-25 - X-dag ordinarie utdelning ALZ 0.00 SEK
2023-05-17 - Kvartalsrapport 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2022-11-01 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning ALZ 0.00 SEK
2022-05-19 - Kvartalsrapport 2022-Q1
2022-05-18 - Årsstämma
2022-02-24 - Bokslutskommuniké 2021
2021-10-28 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-05-19 - X-dag ordinarie utdelning ALZ 0.00 SEK
2021-05-19 - Kvartalsrapport 2021-Q1
2021-05-18 - Årsstämma
2021-02-26 - Bokslutskommuniké 2020
2020-10-29 - Kvartalsrapport 2020-Q3
2020-08-26 - Kvartalsrapport 2020-Q2
2020-05-17 - X-dag ordinarie utdelning ALZ 0.00 SEK
2020-05-15 - Kvartalsrapport 2020-Q1
2020-05-14 - Årsstämma
2020-02-27 - Extra Bolagsstämma 2020
2020-02-26 - Bokslutskommuniké 2019
2019-10-25 - Kvartalsrapport 2019-Q3
2019-08-28 - Kvartalsrapport 2019-Q2
2019-05-17 - X-dag ordinarie utdelning ALZ 0.00 SEK
2019-05-17 - Kvartalsrapport 2019-Q1
2019-05-16 - Årsstämma
2019-02-26 - Bokslutskommuniké 2018
2018-10-26 - Kvartalsrapport 2018-Q3
2018-08-29 - Kvartalsrapport 2018-Q2
2018-05-18 - X-dag ordinarie utdelning ALZ 0.00 SEK
2018-05-18 - Kvartalsrapport 2018-Q1
2018-05-17 - Årsstämma
2018-02-27 - Bokslutskommuniké 2017
2017-11-03 - Kvartalsrapport 2017-Q3
2017-08-29 - Kvartalsrapport 2017-Q2
2017-05-19 - Kvartalsrapport 2017-Q1
2017-05-18 - X-dag ordinarie utdelning ALZ 0.00 SEK
2017-05-17 - Årsstämma
2017-02-24 - Bokslutskommuniké 2016
2016-11-28 - Kvartalsrapport 2016-Q3
2016-08-29 - Kvartalsrapport 2016-Q2
2016-05-19 - X-dag ordinarie utdelning ALZ 0.00 SEK
2016-05-18 - Årsstämma
2016-05-18 - Kvartalsrapport 2016-Q1
2016-02-26 - Bokslutskommuniké 2015

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Alzinova är ett bioteknikbolag. Bolaget är specialiserat inom terapeutiskt behandling av Alzheimers och bedriver idag forskning och utveckling av peptider som vidareutvecklas som vaccin. Utöver utvecklar bolaget även diverse forskningsverktyg inom arbetsområdet. Störst verksamhet återfinns inom den nordiska marknaden. Bolaget grundades under 2011 och har sitt huvudkontor i Göteborg.
2025-04-24 13:00:00

Alzinova AB (publ) (ticker: ALZ) is pleased to announce the release of the drug substance for its upcoming Phase 2 clinical trial of the vaccine candidate ALZ-101 in early Alzheimer’s disease. This milestone enables the production of the final drug product, setting the stage for the study to begin in 2H 2025.

The drug substance was produced by Polypeptide Laboratories in Strasbourg, France, adhering to the GMP standards required for pharmaceutical manufacturing processes. Alzinova and Polypeptide Laboratories will continue their partnership to refine and optimize the manufacturing process in preparation for late-stage clinical trials. This collaboration will focus on enhancing production efficiency, ensuring scalability, and meeting stringent regulatory requirements to support the future development and potential commercialization of the vaccine candidate ALZ-101.

We really appreciate Alzinova’s trust in PolyPeptide and are proud to be their partner in the manufacturing of ALZ-101 for this important milestone. We are excited to be on this journey with Alzinova and are looking forward to celebrating future milestones together!”, says Stephane Varray, Chief Commercial Officer, PolyPeptide Group

For more information, please contact:
Tord Labuda, CEO
E-mail: info@alzinova.com

About Alzinova AB
Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, where the starting point is to attack toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 40 million affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com